Skip to main content

Boundless Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Business Officer, Neil Abdollahian, will present at the 22nd Annual Needham Healthcare Conference which will take place virtually. Presentation details are as follows:

Date: Tuesday, April 18, 2023

Time: 4:30 – 5:10 PM ET

About Boundless Bio

Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.76
+5.49 (2.48%)
AAPL  272.19
+0.35 (0.13%)
AMD  201.06
+2.95 (1.49%)
BAC  54.26
-0.29 (-0.53%)
GOOG  303.75
+5.69 (1.91%)
META  664.45
+14.95 (2.30%)
MSFT  483.98
+7.86 (1.65%)
NVDA  174.14
+3.20 (1.87%)
ORCL  180.03
+1.57 (0.88%)
TSLA  483.37
+16.11 (3.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.